Corton Capital’s Entrada Therapeutics TRDA Stock Holding History

Corton Capital’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$225K	Buy	38,849 +10,094	+35%	+$59.1K	0.55%	79
2025 Q2	$193K	Buy	+28,755	New	+$231K	0.23%	249
2024 Q4	–	Sell	-57,849	Closed	-$924K	–	641
2024 Q3	$924K	Buy	57,849 +2,876	+5%	+$45.3K	0.45%	6
2024 Q2	$783K	Buy	54,973 +13,831	+34%	+$197K	0.41%	5
2024 Q1	$583K	Buy	41,142 +12,566	+44%	+$178K	0.21%	115
2023 Q4	$431K	Buy	28,576 +18,091	+173%	+$268K	0.14%	207
2023 Q3	$166K	Sell	10,485 -7,582	-42%	-$119K	0.08%	337
2023 Q2	$274K	Buy	+18,067	New	+$249K	0.13%	238

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Corton Capital's TRDA Position: Q3 2025 in Review

Corton Capital increased its Entrada Therapeutics (TRDA) stake by 35% in Q3 2025, buying an estimated $59.1K and bringing the position to 38,849 shares worth $225K. The position accounts for 0.55% of the portfolio, ranked #79.

Corton Capital first reported a position in TRDA in Q2 2023 and has held it in 8 quarters since. The position peaked at $924K in Q3 2024. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

Corton Capital held 38,849 shares of Entrada Therapeutics worth $225K as of Q3 2025.
Corton Capital bought 10,094 Entrada Therapeutics shares in Q3 2025, an estimated $59.1K.
Entrada Therapeutics made up 0.55% of Corton Capital's portfolio in Q3 2025, its #79 holding.
Corton Capital first reported a position in Entrada Therapeutics in Q2 2023 and has held it in 8 quarters since.
Corton Capital's Entrada Therapeutics position peaked at $924K in Q3 2024.
117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.